Adcock sees lower full-year profit; shares fall

Adcock Ingram, South Africa’s second-biggest drug maker, said on Monday it expected full-year profit to fall by as much as 22%, stung by a once-off charge related to a black economic empowerment (BEE) deal.

Adcock Ingram, which makes painkillers and other over-the-counter drugs, said it took a R269-million share-based payment charge in relation to a sale last year to black investors.

The company said last November it would sell a 13 percent stake to black investors for R1,3-billion, in order to meet government targets on black ownership.

As a result, the company said it expected to post a decline of between 19% and 22% in headline earnings per share for the year until the end of September.

Headline Earnings on Investopedia (EPS) is the main gauge of profit in South Africa and excludes certain one-time items. Excluding the charges, headline EPS most likely increased from 13% to 16%, Adcock said.

Shares in the company, which were up 20% so far this year, fell 1,18% to R64,65, underperforming a slightly higher all-share index.

Adcock, South Africa’s top over-the-counter drugs maker, has been squeezed as cost-sensitive customers cut the size of their purchases or move to cheaper brands.

However, lower interest rates and tentative economic recovery are encouraging consumers to spend more freely once again.—Reuters


Client Media Releases

ITWeb, VMware second CISO survey under way
Doctoral study on leveraging the green economy
NWU's LLB degree receives full accreditation
Trusts must register as home builders